Myeloid-derived suppressor cells: a novel therapeutic target (Q37393000)

20 August 2017

1 reference

title

Myeloid-derived suppressor cells: a novel therapeutic target (English)

1 reference

20 August 2017

Jennifer S Ko

1

1 reference

20 August 2017

Ronald M Bukowski

series ordinal

2

1 reference

20 August 2017

James H Fincke

series ordinal

3

1 reference

20 August 2017

publication date

1 March 2009

1 reference

20 August 2017

published in

Current Oncology Reports

1 reference

20 August 2017

volume

11

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

87-93

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-009-0014-6

20 August 2017

exact match

0 references

cites work

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS11912-009-0014-6

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-009-0014-6

Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-009-0014-6

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-009-0014-6

L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-009-0014-6

Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-009-0014-6

Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-009-0014-6

Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-009-0014-6

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

12 December 2020

Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine

1 reference

12 December 2020

Differential induction of hematopoiesis and immune suppressor cells in the bone marrow versus in the spleen by Lewis lung carcinoma variants.

1 reference

12 December 2020

Interferons, immunity and cancer immunoediting

1 reference

12 December 2020

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

1 reference

12 December 2020

Immune-mediated dormancy: an equilibrium with cancer

1 reference

12 December 2020

1 reference

12 December 2020

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma

1 reference

12 December 2020

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma

1 reference

12 December 2020

Regulatory T cells and cancer

1 reference

12 December 2020

1 reference

12 December 2020

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

1 reference

12 December 2020

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients

1 reference

12 December 2020

Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on.

1 reference

12 December 2020

Antiangiogenic therapy for cancer: an update

1 reference

12 December 2020

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

1 reference

12 December 2020

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

1 reference

12 December 2020

Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer

1 reference

12 December 2020

Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors

1 reference

12 December 2020

Can tumor angiogenesis be inhibited without resistance?

1 reference

12 December 2020

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

1 reference

12 December 2020

Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice.

1 reference

12 December 2020

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

1 reference

12 December 2020

Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

1 reference

12 December 2020

Targeted therapies to improve tumor immunotherapy

1 reference

12 December 2020

Modes of resistance to anti-angiogenic therapy

1 reference

12 December 2020

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion

1 reference

12 December 2020

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

1 reference

12 December 2020

Chemotherapy for metastatic melanoma: time for a change?

1 reference

12 December 2020

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

1 reference

12 December 2020

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

1 reference

12 December 2020

L-arginine availability regulates T-lymphocyte cell-cycle progression

1 reference

12 December 2020

The MAPK pathway in melanoma

1 reference

12 December 2020

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

1 reference

12 December 2020

Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway

1 reference

12 December 2020

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

1 reference

12 December 2020

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

1 reference

12 December 2020

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

1 reference

12 December 2020

The role of myeloid cells in the promotion of tumour angiogenesis

1 reference

12 December 2020

Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

1 reference

12 December 2020

Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Regulatory T cells and treatment of cancer

1 reference

12 December 2020

Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

1 reference

12 December 2020

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

1 reference

12 December 2020

Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function

1 reference

12 December 2020

Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.

1 reference

12 December 2020

Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy

1 reference

12 December 2020

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

1 reference

12 December 2020

Immunosuppressive strategies that are mediated by tumor cells

1 reference

12 December 2020

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells

1 reference

12 December 2020

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

1 reference

12 December 2020

The three Es of cancer immunoediting

1 reference

12 December 2020

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

1 reference

12 December 2020

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

1 reference

12 December 2020

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression

1 reference

12 December 2020

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

1 reference

12 December 2020

Nitric oxide and thiol redox regulation of Janus kinase activity

1 reference

12 December 2020

1 reference

12 December 2020

Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed

1 reference

12 December 2020

10.1007/S11912-009-0014-6

Identifiers

DOI

1 reference

20 August 2017

1 reference